These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15661541)

  • 1. Phase II trials of drug combinations: fairytales or fact?
    Verweij J
    Eur J Cancer; 2005 Jan; 41(2):195-6. PubMed ID: 15661541
    [No Abstract]   [Full Text] [Related]  

  • 2. Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study.
    Nooij MA; Whelan J; Bramwell VH; Taminiau AT; Cannon S; Hogendoorn PC; Pringle J; Uscinska BM; Weeden S; Kirkpatrick A; Glabbeke Mv; Craft AW;
    Eur J Cancer; 2005 Jan; 41(2):225-30. PubMed ID: 15661546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy of sarcoma.
    Chugh R; Baker LH
    Expert Opin Pharmacother; 2009 Aug; 10(12):1953-63. PubMed ID: 19558336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current topics of chemotherapy for sarcoma and bone neoplasms].
    Hirata T; Ando M
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):415-419. PubMed ID: 18401919
    [No Abstract]   [Full Text] [Related]  

  • 5. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial.
    Brady MS; Brown K; Patel A; Fisher C; Marx W
    Melanoma Res; 2009 Apr; 19(2):106-11. PubMed ID: 19282789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
    Hartmann JT
    Anticancer Drugs; 2007 Mar; 18(3):245-54. PubMed ID: 17264755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying emerging drugs for very rare conditions.
    Miles KA; Packer C; Stevens A
    QJM; 2007 May; 100(5):291-5. PubMed ID: 17456610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials referral resource. Current clinical trials in rhabdomyosarcoma.
    Anderson BD; Schoenfeldt M
    Oncology (Williston Park); 2005 Sep; 19(10):1319-20, 1330. PubMed ID: 16285226
    [No Abstract]   [Full Text] [Related]  

  • 10. Complexities in interpretation of osteosarcoma clinical trial results.
    Hunsberger S; Freidlin B; Smith MA
    J Clin Oncol; 2008 Jun; 26(18):3103-4; author reply 3104-5. PubMed ID: 18565905
    [No Abstract]   [Full Text] [Related]  

  • 11. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
    Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
    Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapy for metastatic urothelial carcinoma.
    Lin CC; Hsu CH; Pu YS; Vogelzang NJ
    BJU Int; 2008 Apr; 101(7):795-803. PubMed ID: 18070193
    [No Abstract]   [Full Text] [Related]  

  • 13. Response rate as an endpoint in clinical trials.
    George SL
    J Natl Cancer Inst; 2007 Jan; 99(2):98-9. PubMed ID: 17227987
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T-cell lymphoma.
    Lennard A
    Br J Haematol; 2007 Apr; 137(2):170; author reply 171. PubMed ID: 17391498
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
    Jessen C; Agerbaek M; Von Der Maase H
    Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adjuvant chemotherapy in the treatment of sarcomas].
    Fayette J; Blay JY
    Bull Cancer; 2006 Mar; 93(3):257-61. PubMed ID: 16567312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteosarcoma: the same old drugs or more?
    Bielack SS; Marina N; Ferrari S; Helman LJ; Smeland S; Whelan JS; Reaman GH
    J Clin Oncol; 2008 Jun; 26(18):3102-3; author reply 3104-5. PubMed ID: 18565904
    [No Abstract]   [Full Text] [Related]  

  • 18. Is response rate relevant to the phase II trial design of targeted agents?
    Dowlati A; Fu P
    J Clin Oncol; 2008 Mar; 26(8):1204-5. PubMed ID: 18285601
    [No Abstract]   [Full Text] [Related]  

  • 19. Epothilones and the next generation of phase III trials for prostate cancer.
    Bhandari MS; Hussain M
    BJU Int; 2005 Aug; 96(3):296-302. PubMed ID: 16042717
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase III trials in oncology: setting standards of care?
    Seeber S; Braun AH
    Nat Clin Pract Oncol; 2005 Sep; 2(9):426-7. PubMed ID: 16264993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.